📬 GI Cancer Intelligence Digest — Week 2026-W30

A first-in-human mutant KRAS vaccine intercepts high-risk pancreatic cancer, spatial multi-omics maps colorectal micrometastasis biology, and durvalumab reintroduction shows benefit in advanced biliary tract cancer.

⚡ TL;DR

📄 Publications

KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial. — Confirmed ORR 63.3% in 30 treatment-naive patients
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. — In tsMHC-II-positive patients, tislelizumab plus chemotherapy raised mPR to 61.8% vs 26.5% (p=0.003)
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. — Vaccination elicited significant mKRAS-specific T cell response in 18/20 participants (90%)
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers. — Six patients (23.1%) were downstaged to resectable and underwent resection, all recurrence-free

🐦 Twitter / 🦋 Bluesky

First-in-human mutant KRAS vaccine intercepts high-risk pancreatic cancer — First study demonstrating feasibility of a mutant KRAS targeted vaccine in high-risk individuals with persistent T cells ~2 years
Spatial multi-omics maps colorectal micrometastasis biology — Study deconstructs clonal evolution of micrometastases and TME differences between micro- and macrometastases in CRC
Pan-Asian adapted ESMO HCC guidelines published — Pan-Asian panel adapts ESMO HCC guidelines with 84.2% concordance across 10 Asian societies; 65 recommendations reviewed, 16 revised
Dominant-negative TGFβ armored GPC3 CAR-T shows activity in HCC — Dominant negative TGFb armored GPC3 CAR published in Nature showed 44% ORR and 14.2 mo mOS in HCC, many 3L+
Durvalumab plus GemCis reintroduction shows benefit in advanced biliary tract cancer — Multinational real-world analysis suggests benefit for cisplatin-gemcitabine-durvalumab reintroduction versus second line in advanced BTC

Full details below ↓

📄 What's Being Published

Manuscripts:

KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial. — Cui Jiujie et al., Nat Med

In 30 treatment-naive patients, the confirmed objective response rate was 63.3% (95% CI = 43.9–80.1) with intravenous liposomal HRS-4642 combined with nab-paclitaxel and gemcitabine. Grade ≥3 treatment-related adverse events occurred in 90.3% of patients, primarily hematologic toxicities consistent with AG chemotherapy.

Clinical bottom line: Intravenous liposomal HRS-4642 plus nab-paclitaxel/gemcitabine achieves a 63.3% confirmed ORR in first-line KRAS G12D PDAC, with hematologic toxicity driven by the chemotherapy backbone.

Read full article →

Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. — Xu Zhiyuan et al., Cancer Cell

In tsMHC-II-positive patients, adding tislelizumab to chemotherapy significantly increased the major pathological response rate compared with chemotherapy alone (61.8% vs. 26.5%, p = 0.003). The tsMHC-II-positive subgroup also demonstrated a higher pathological complete response rate (32.4% vs. 5.9%, p = 0.006) than tsMHC-II-negative patients.

Clinical bottom line: Tumor-specific MHC class II expression identifies the gastric cancer patients who derive benefit from perioperative tislelizumab, with the major pathological response gain confined to the tsMHC-II-positive subgroup.

Read full article →

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. — Haldar S Daniel et al., Cancer Discov

Vaccination elicited a significant mKRAS-specific T cell response in 18/20 participants (90%), and over a median follow-up of 16.5 months, no participants developed PDAC. T cell responses persisted up to two years in high-risk individuals.

Clinical bottom line: A six-mutation KRAS peptide vaccine is safe and generates durable T cell responses persisting up to two years in high-risk individuals, supporting its advancement for pancreatic cancer interception.

Read full article →

🔗 Also discussed on social media →

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes. — Nonnekens Julie et al., Clin Cancer Res

Several TRT agents are approved for treating various cancers, including prostate cancer and gastroenteropancreatic neuroendocrine tumors, or their microenvironment. The review surveys combination strategies designed to extend benefit beyond what monotherapy achieves at relapse.

Clinical bottom line: Combination strategies with hormone therapy, DNA damage repair inhibitors, immunotherapy, and external beam radiation are framed as the path to extend targeted radionuclide therapy benefit beyond monotherapy relapse.

Read full article →

Non-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer. — Zhang Qianyu et al., Clin Cancer Res

In heavily pretreated metastatic colorectal cancer, the overall response rate and disease control rate reached 33% and 63%, respectively. Two treatment-related deaths occurred — one due to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and one due to intestinal fistula following rapid tumor regression.

Clinical bottom line: GCC-targeted CAR-T cells show proof-of-concept activity in heavily pretreated colorectal cancer but with limited durability and serious toxicity, including two treatment-related deaths, requiring optimization before broader use.

Read full article →

Spatial multi-omics landscape of colorectal cancer macro- and micrometastases. — Liu Yang et al., Cancer Cell

The study mapped 49 tumors from 19 patients, encompassing paired primary CRC and matched liver and lung metastases, revealing that liver micrometastases arose from early clonal divergences and harbored a stem-like, quiescent state consistent with metastatic dormancy. A CLiMi-specific six-gene signature was identified as associated with MRD status, disease-free survival, and chemotherapy resistance across multiple independent cohorts.

Clinical bottom line: Spatial multi-omics of colorectal metastases reveals a dormant stem-like state in liver micrometastases and a six-gene signature tied to minimal residual disease and chemotherapy resistance.

Read full article →

Colorectal Cancer Treatment Delay Thresholds and Metastasis Risk. — Nguyen Chi M et al., JAMA Netw Open

Among 11,927 patients, 1,438 (12.1%) developed metastasis over 3 years. For the surgery plus adjuvant therapy pathway, time-to-initiation intervals of 4 to 46 days (sHR, 1.27; 95% CI, 1.04–1.55) and 47 days or longer (sHR, 1.55; 95% CI, 1.08–2.23) were significantly associated with increased metastasis risk versus zero to 3 days.

Clinical bottom line: Treatment initiation delays in nonmetastatic colorectal cancer are associated with higher, pathway-specific 3-year metastasis risk, supporting pathway-tailored benchmarks for timely care.

Read full article →

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. — Lopez-Lopez Victor et al., J Natl Cancer Inst

Continuation of adjuvant FOLFIRINOX was associated with longer OS compared with no adjuvant chemotherapy (median OS, 42.0 vs. 25.8 months; HR, 0.58; 95% CI, 0.43–0.79; p < 0.001). Switching to adjuvant Gem/Nab did not confer a survival benefit in this group (HR, 0.84; 95% CI, 0.61–1.15; p = 0.27).

Clinical bottom line: Adjuvant chemotherapy benefit in resected borderline/locally advanced pancreatic cancer is regimen-dependent: postoperative continuation of FOLFIRINOX confers a survival advantage, while de-escalation or adjuvant therapy after neoadjuvant Gem/Nab does not.

Read full article →

Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers. — Shah Priyanshi et al., JCO Precis Oncol

Six patients (23.1%) were restaged to resectable from advanced disease after ICI therapy and underwent resection; all remained recurrence-free at last follow-up. Among first-line therapy patients, the 2-year OS was 73% (95% CI, 56% to 94%), with a median time to discontinuation of 9.9 months (95% CI, 5.7 to 14.5 months).

Clinical bottom line: Immune checkpoint inhibitor therapy in MSI-H biliary tract cancer produces durable responses and downstages nearly a quarter of advanced patients to resectable disease, supporting up-front dMMR/MSI-H testing.

Read full article →

🔗 Also discussed on social media →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

First-in-human mutant KRAS vaccine intercepts high-risk pancreatic cancer

This is the first study to demonstrate the feasibility of a mutant KRAS targeted vaccine not in established pancreatic cancer but in high-risk individuals, with T cell responses in 90% persisting up to two years and no participants developing PDAC over a median follow-up of 16.5 months. The central question for oncologists: could vaccination against mutant KRAS shift pancreatic cancer care toward prevention in high-risk cohorts?

Discussed by: @Aiims1742, @Aiims1742, @EladSharonMD, @Gio_Marchegiani

→ View representative tweet

Spatial multi-omics maps colorectal micrometastasis biology

Covering 49 tumors from 19 patients with paired primary CRC and matched liver and lung metastases, this spatial multi-omics work deconstructs the clonal evolution of micrometastases and TME differences between micro- and macrometastases. Liver micrometastases arose from early clonal divergences and harbored a stem-like, quiescent state consistent with metastatic dormancy — prompting debate over whether spatially validated micrometastasis biomarkers can refine surveillance and adjuvant strategy in colorectal cancer.

Discussed by: @OncoAlert, @OncoAlert

→ View representative tweet

Pan-Asian adapted ESMO HCC guidelines published

A pan-Asian panel adapted ESMO HCC guidelines with 84.2% concordance across 10 Asian societies; of 65 recommendations reviewed, 16 were revised. IO combinations remain preferred first-line in advanced HCC and routine ctDNA is still not recommended — leaving specialists to weigh how well these adapted recommendations reconcile Western and Asian evidence for HCC management.

Discussed by: @DraMartinezLago, @K_Yadavir, @ArndtVogel, @hongjaechon

→ View representative tweet

Dominant-negative TGFβ armored GPC3 CAR-T shows activity in HCC

A dominant-negative TGFβ armored GPC3 CAR-T published in Nature demonstrated a 44% ORR and a median OS of 14.2 months in HCC, a population in which many patients were third-line or beyond. The open question for hepatocellular carcinoma specialists: can armored GPC3 CAR-T become a viable cell therapy option in advanced disease?

Discussed by: @EladSharonMD, @MikeChuongMD

→ View representative tweet

Durvalumab plus GemCis reintroduction shows benefit in advanced biliary tract cancer

A multinational real-world analysis examined cisplatin-gemcitabine-durvalumab reintroduction versus second-line therapy in advanced biliary tract cancer. In the MSI-H subset, ICI therapy yielded a 2-year OS of 73% (95% CI, 56% to 94%), and 6 patients (23.1%) were restaged to resectable from advanced disease, all remaining recurrence-free at last follow-up — contextualizing the debate over whether durvalumab-chemotherapy reintroduction is preferable to switching regimens at progression.

Discussed by: @ArndtVogel, @SKamath_MD

→ View representative tweet

Concurrent SBRT and KRAS inhibition synergize in preclinical pancreatic cancer

A preclinical study demonstrates that concurrent stereotactic body radiation therapy and KRAS inhibition synergistically improve pancreatic cancer treatment, forming the basis for a pending clinical trial. In borderline/locally advanced PDAC, a neoadjuvant early SBRT regimen with chemoimmunotherapy achieved a 36.4% response rate, 100% disease control, with 27.3% undergoing successful R0 resection, and was associated with longer progression-free survival (12.5 vs. 6.6 months) — positioning the combination as a candidate for clinical translation.

Discussed by: @Aiims1742, @OncoAlert

→ View representative tweet

Radiation therapy advocated for appropriate HCC patients in IJROBP editorial

An editorial in IJROBP advocates for routine discussion of radiation therapy for appropriate HCC patients. Separately, discussion addressed outcomes of the HIMALAYA study and how liver function can be maintained while preserving hepatic function — with oncologists debating whether radiation therapy should be more routinely integrated into multidisciplinary HCC decision-making.

Discussed by: @MikeChuongMD, @GiOncNow

→ View representative tweet

Cancer-associated thrombosis in GI cancers

A review examines local and systemic thrombotic complications in cirrhotic patients with HCC, addressed alongside a broader review of cancer-associated thrombosis specifically in GI cancers. The clinical question for oncologists managing this population: how should thrombosis risk be handled across GI malignancies, including cirrhotic HCC patients?

Discussed by: @Erman_Akkus, @HepatomaRes

→ View representative tweet

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @hongjaechon: 🚨 Durvalumab plus GemCis sustains OS benefit at 4-year f/u in advanced BTC @JAMAOnc  👉 mOS: 13.0 vs 11.4 mo (HR 0.75) 👉 48-mo OS rate: 11.8% vs 4.3% 👉 Safety consistent, no new signals
DOI: https://t.co/IOxnMKRyYA
@ASCO @EASLnews @ILCAnews  #TOPAZ1 #BiliaryTractCancer #Durvalumab #Cholangiocarcinoma

🔖 6 ❤️ 28 🔁 12 👁 2,169